Synergistic Effects of Combined PROTAC-based EZH2 Degrader and METTL3 Inhibitor in Burkitt’s Lymphoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
EZH2 is a methyltransferase that is a critical target for lymphoma treatment. However, it is not yet widely used in clinical settings. PROteolysis TArgeting Chimeras (PROTACs) represent a novel therapeutic strategy aimed at eliminating proteins that have been a challenging target using conventional small molecules. In our previous research, we compared the small molecules-based EZH2 inhibitor used in clinical settings with a PROTAC-based EZH2 degrader. We found that the PROTAC-based degrader was significantly more effective. Building on this, we further investigated the effects of combining the PROTAC-based EZH2 degrader (dEZH2) with a METTL3 inhibitor, both of which have demonstrated effectiveness in inhibiting cell proliferation and inducing apoptosis in Burkitt’s lymphoma. Using the CCK-8 assay, we found that both drugs, alone and in combination, significantly inhibited Daudi and Ramos cell growth in a dose-dependent manner. The combined treatment markedly suppressed cell proliferation and induced apoptosis, as confirmed by Annexin V/PI staining. Our results revealed G2/M phase arrest with a significant decrease in the G0/G1 phase by flow cytometry. Our study also showed increased levels of cleaved PARP, cleaved caspase-3, tumor protein p53 (TP53), and PUMA using the western blot technique, indicating enhanced p53-dependent apoptosis. Our findings suggest that the combination therapy of dEZH2 and iMETTL3 could be a promising approach in the treatment of Burkitt’s lymphoma.
Abstract
EZH2 is a methyltransferase that is a critical target for lymphoma treatment. However, it is not yet widely used in clinical settings. PROteolysis TArgeting Chimeras (PROTACs) represent a novel therapeutic strategy aimed at eliminating proteins that have been a challenging target using conventional small molecules. In our previous research, we compared the small molecules-based EZH2 inhibitor used in clinical settings with a PROTAC-based EZH2 degrader. We found that the PROTAC-based degrader was significantly more effective. Building on this, we further investigated the effects of combining the PROTAC-based EZH2 degrader (dEZH2) with a METTL3 inhibitor, both of which have demonstrated effectiveness in inhibiting cell proliferation and inducing apoptosis in Burkitt’s lymphoma. Using the CCK-8 assay, we found that both drugs, alone and in combination, significantly inhibited Daudi and Ramos cell growth in a dose-dependent manner. The combined treatment markedly suppressed cell proliferation and induced apoptosis, as confirmed by Annexin V/PI staining. Our results revealed G2/M phase arrest with a significant decrease in the G0/G1 phase by flow cytometry. Our study also showed increased levels of cleaved PARP, cleaved caspase-3, tumor protein p53 (TP53), and PUMA using the western blot technique, indicating enhanced p53-dependent apoptosis. Our findings suggest that the combination therapy of dEZH2 and iMETTL3 could be a promising approach in the treatment of Burkitt’s lymphoma.
참고문헌 (30)
- Chen S, "Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques", Eur J Med Chem, 262, pp.115911~ (2023)[DOI]
- Paudel RR, "Targeted protein degradation via lysosomes", Biochemistry, 62, pp.564~579 (2023)[DOI]
- Crunkhorn S, "Developing antibody-based PROTACs", Nat Rev Drug Discov, 21, pp.795~ (2022)[DOI]
- Békés M, "PROTAC targeted protein degraders : the past is prologue", Nat Rev Drug Discov, 21, pp.181~200 (2022)[DOI]
- Li X, "Proteolysis-targeting chimera(PROTAC)for targeted protein degradation and cancer therapy", J Hematol Oncol, 13, pp.50~ (2020)[DOI]
- Ma A, "Discovery of a first-in-class EZH2 selective degrader", Nat Chem Biol, 16, pp.214~222 (2020)[DOI]
- Jeong Y, "Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma : a comprehensive study on the combined effects of MS1943 and Ibrutinib", Front Oncol, 13, pp.1252658~ (2023)[DOI]
- Xie H, "Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2complex in lymphoma", Bioorg Chem, 140, pp.106762~ (2023)[DOI]
- Kim SB, "Dual targeting of EZH2 degradation and EGFR", HER2 inhibition for enhanced efficacy against Burkitt’s lymphoma, 2023, pp.15, 4472~
- Zeng C, "Roles of METTL3 in cancer : mechanisms and therapeutic targeting", J Hematol Oncol, 13, pp.117~ (2020)[DOI]
- Li Y, "METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions", Nat Commun, 13, pp.6350~ (2022)[DOI]
- Li J, "METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells", Cell Death Discov, 9, pp.405~ (2023)[DOI]
- Meng S, "NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc", Sci Rep, 13, pp.8606~ (2023)[DOI]
- Li M, "METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4", Leukemia, 36, pp.2586~2595 (2022)[DOI]
- Yankova E, "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia", Nature, 593, pp.597~601 (2021)[DOI]
- Ferry JA, "Burkitt’s lymphoma: clinicopathologic features and differential diagnosis", Oncologist, 11, pp.375~383 (2006)[DOI]
- Schmitz R, "Oncogenic mechanisms in Burkitt lymphoma", Cold Spring Harb Perspect Med, 4, pp.a014282~ (2014)[DOI]
- Los M, "Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling", Mol Biol Cell, 13, pp.978~988 (2002)[DOI]
- Boulares AH, "Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells", J Biol Chem, 274, pp.22932~22940 (1999)[DOI]
- Yu J, "PUMA, a potent killer with or without p53", Oncogene, 27(Suppl 1), pp.S71~S83 (2008)[DOI]
- Han CW, "Structural basis of the p53 DNA binding domain and PUMA complex", Biochem Biophys Res Commun, 548, pp.39~46 (2021)[DOI]
- Qi SM, "PROTAC : an effective targeted protein degradation strategy for cancer therapy", Front Pharmacol, 12, pp.692574~ (2021)[DOI]
- Neklesa TK, "Targeted protein degradation by PROTACs", Pharmacol Ther, 174, pp.138~144 (2017)[DOI]
- Liu Z, "An overview of PROTACs : a promising drug discovery paradigm", Mol Biomed, 3, pp.46~ (2022)[DOI]
- Bricelj A, "E3 ligase ligands in successful PROTACs : an overview of syntheses and linker attachment points", Front Chem, 9, pp.707317~ (2021)[DOI]
- Dale B, "Advancing targeted protein degradation for cancer therapy", Nat Rev Cancer, 21, pp.638~654 (2021)[DOI]
- Velez J, "Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting noncanonical oncogenic functions of EZH2", Eur J Med Chem, 267, pp.116154~ (2024)[DOI]
- Liu Z, "Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2", J Med Chem, 64, pp.2829~2848 (2021)[DOI]
- Diehl CJ, "Discovery of small molecule ligands for the von Hippel-Lindau(VHL)E3 ligase and their use as inhibitors and PROTAC degraders", Chem Soc Rev, 51, pp.8216~8257 (2022)[DOI]
- An S, "Small-molecule PROTACs : an emerging and promising approach for the development of targeted therapy drugs", EBioMedicine, 36, pp.553~562 (2018)[DOI]